12 results
S-3
EX-1.2
DSGN
Design Therapeutics, Inc.
27 Apr 22
Shelf registration
5:24pm
, accounting, regulatory and tax advisors to the extent it deemed appropriate. (c) Research Analyst Independence. The Company acknowledges
DEF 14A
DSGN
Design Therapeutics, Inc.
27 Apr 22
Definitive proxy
4:25pm
REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE Independence of the Board of Directors As required under the Nasdaq Stock Market (“Nasdaq … Chairperson and Chief Executive Officer reinforces the independence of our Board of Directors in its oversight of our business and affairs. In addition, we have
10-K
ti9p wouy
10 Mar 22
Annual report
4:17pm
8-K
EX-3.2
fnxe4tg31syooqp4ri29
30 Mar 21
Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:44pm
424B4
ci68vr
26 Mar 21
Prospectus supplement with pricing info
5:11pm
S-1/A
54bqcjfdzyu50m0bq
22 Mar 21
IPO registration (amended)
6:11am
S-1
EX-3.4
x9646z
5 Mar 21
IPO registration
5:18pm
S-1
jbnrd
5 Mar 21
IPO registration
5:18pm
DRS
uhrr q2iktbio1udi
26 Jan 21
Draft registration statement
12:00am
- Prev
- 1
- Next